BioPharmSignal logoBioPharmSignal

Biotech News

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Salarius Pharmaceuticals (SLRX)Salarius PharmaceuticalsPartnership

Partnership supported by funding from Google Cloud will increase Decoy's computational peptide design bandwidth by 25-100x CAMBRIDGE, Mass. and HOUSTON, March 11, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable

Related news

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

NRIXNurix Therapeutics2026-10-05 11:00 EST

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

MGNXMacroGenics2026-08-11 20:05 EST

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

REGNRegeneron Pharmaceuticals2026-10-01 05:00 EST

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

RVMDRevolution Medicines2026-08-10 10:01 EST

Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration

IDYAIDEAYA Biosciences2026-08-19 10:00 EST

IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

ELVNEnliven Therapeutics2026-08-31 22:05 EST

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

CGEMCullinan Therapeutics, Inc.2026-09-21 16:00 EST

Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

ELVNEnliven Therapeutics2026-09-03 20:05 EST

Enliven Therapeutics to Present at Upcoming Investor Conferences

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

View all latest news

Salarius Pharmaceuticals

Salarius Pharmaceuticals is a biotechnology company focused on oncology and epigenetic or related cancer biology. Its story is built around seeking targeted cancer therapies for difficult tumors.

Recent company news

SLRXSalarius Pharmaceuticals2026-04-27 12:45 EST

Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston

SLRXSalarius Pharmaceuticals2026-04-09 12:36 EST

Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline

SLRXSalarius Pharmaceuticals2026-04-06 13:15 EST

Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026

SLRXSalarius Pharmaceuticals2026-04-02 13:00 EST

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

SLRXSalarius Pharmaceuticals2026-03-11 12:30 EST

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States